| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 1995;26:1683-1690.)
© 1995 American Heart Association, Inc.
Articles |
From SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (F.C.B., P.G.L., W.J.P., G.F.), and New Frontiers Science Park, Harlow, UK (K.A.Al-B., C.D.B., D.C.H., M.H.H., S.J.B., A.J.H.).
Correspondence to Frank C. Barone, PhD, Department of Cardiovascular Pharmacology, UW2521, SmithKline Beecham Pharmaceuticals, 709 Swedeland Rd, King of Prussia, PA 19406-0939.
Background and Purpose Excessive calcium entry into depolarized neurons contributes significantly to cerebral tissue damage after ischemia. We evaluated the ability of a novel neuronal calcium channel blocker, SB 201823-A, to block central neuronal calcium influx in vitro and to reduce ischemic injury in two rodent models of focal stroke.
Methods Patch-clamp electrophysiology and intracellular Ca2+ imaging in rat hippocampal and cerebellar neurons were used to determine effects on neuronal calcium channel activity. Middle cerebral artery occlusion was performed in Fisher 344 rats and CD-1 mice to determine the effects on rodent focal ischemic injury and neurological deficits. Cardiovascular monitoring in conscious rats was conducted to determine cardiovascular liabilities of the compound.
Results In cultured rat hippocampal cells, calcium current measured at plateau was reduced by 36±8% and 89±4% after 5 and 20 µmol/L SB 201823-A, respectively. In cerebellar granule cells in culture, pretreatment with 2.5 µmol/L SB 201823-A totally prevented initial calcium influx and reduced later calcium influx by 50±2.5% after N-methyl-D-aspartate/glycine stimulation (P<.01). KCl depolarizationinduced calcium influx also was reduced by more than 95%. In rats, a single treatment with 10 mg/kg IV SB 201823-A beginning 30 minutes after focal ischemia decreased (P<.05) hemispheric infarct by 30.4% and infarct volume by 29.3% and reduced (P<.05) forelimb deficits by 47.8% and hindlimb deficits by 36.3%. In mice, treatments with 10 mg/kg IP SB 201823-A beginning 30 minutes after focal ischemia significantly reduced infarct volume by 41.5% (P<.01). No blood pressure effects were observed with the therapeutic dose of the compound.
Conclusions These results indicate that the new neuronal calcium channel blocker SB 201823-A can block stimulated calcium influx into central neurons and can provide neuroprotection in two models of focal cerebral ischemia without affecting blood pressure. Data from several different studies now indicate that the neuronal calcium channel antagonists are a promising therapy for the postischemic treatment of stroke.
Key Words: calcium channel blockers cerebral ischemia, focal neuroprotection rats
This article has been cited by other articles:
![]() |
E. Shi, T. Kazui, X. Jiang, N. Washiyama, K. Suzuki, K. Yamashita, and H. Terada NS-7, a novel Na+/Ca2+ channel blocker, prevents neurologic injury after spinal cord ischemia in rabbits J. Thorac. Cardiovasc. Surg., February 1, 2005; 129(2): 364 - 371. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Aoki, M. Tamura, Y. Itoh, T. Seto, K. Nonaka, H. Mukai, and Y. Ukai Effective Plasma Concentration of a Novel Na+/Ca2+ Channel Blocker NS-7 for Its Cerebroprotective Actions in Rats with a Transient Middle Cerebral Artery Occlusion J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 306 - 311. [Abstract] [Full Text] |
||||
![]() |
F. C. Barone, B. Arvin, R. F. White, A. Miller, C. L. Webb, R. N. Willette, P. G. Lysko, and G. Z. Feuerstein Tumor Necrosis Factor-{alpha} : A Mediator of Focal Ischemic Brain Injury Stroke, June 1, 1997; 28(6): 1233 - 1244. [Abstract] [Full Text] |
||||
![]() |
H. Takahashi, J. R. Kirsch, K. Hashimoto, E. D. London, R. C. Koehler, R. J. Traystman, and P. G. Lysko PPBP [4-Phenyl-1-(4-phenylbutyl) Piperidine] Decreases Brain Injury After Transient Focal Ischemia in Rats Stroke, November 1, 1996; 27(11): 2120 - 2123. [Abstract] [Full Text] |
||||
![]() |
A.K. Pringle, C.D. Benham, L. Sim, J. Kennedy, F. Iannotti, L.E. Sundstrom, and D. W. Choi Selective N-Type Calcium Channel Antagonist Omega Conotoxin MVIIA Is Neuroprotective Against Hypoxic Neurodegeneration in Organotypic Hippocampal-Slice Cultures Stroke, November 1, 1996; 27(11): 2124 - 2130. [Abstract] [Full Text] |
||||
![]() |
S. J. Bailey, N. I. Wood, N. A. Samson, A. L. Rothaul, J. C. Roberts, P. D. King, T. C. Hamilton, D. C. Harrison, and A. J. Hunter Failure of Isradipine to Reduce Infarct Size in Mouse, Gerbil, and Rat Models of Cerebral Ischemia Stroke, November 1, 1995; 26(11): 2177 - 2183. [Abstract] [Full Text] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |